Preliminary Final Report
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The report indicates a significant decrease in revenue from ordinary activities compared to the previous year, alongside an increase in losses attributable to the owners. Despite these challenges, the company reported an increase in net assets due to a successful capital raise. No dividends were declared during the financial period.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Optiscan Imaging Limited on 6ix
Earlier from Optiscan Imaging
- Appendix 4G & Corporate Governance Statement
- 2026 Annual Report
- Quarterly Activities/Appendix 4C Cash Flow Report
- Optiscan Signs New Research Agreement for Breast Study
- Head and Neck Study Progressing Ahead of Schedule
Later from Optiscan Imaging
- Optiscan Initiates Head and Neck Cancer Study in the US
- Change of Director's Interest Notice
- Application for quotation of securities - OIL
- Significant Milestone Reached in ACL Digital Pathology Study
- Notification of cessation of securities - OIL
Follow Optiscan Imaging into a list and get an email when it puts out news.
Follow Optiscan Imaging